Europe - Euronext Paris - EPA:SAN - FR0000120578 - Common Stock
The current stock price of SAN.PA is 77.54 EUR. In the past month the price decreased by -6.58%. In the past year, price decreased by -25.73%.
ChartMill assigns a fundamental rating of 4 / 10 to SAN.PA. While SAN.PA is still in line with the averages on profitability rating, there are concerns on its financial health.
Over the last trailing twelve months SAN.PA reported a non-GAAP Earnings per Share(EPS) of 7.6. The EPS decreased by -5.35% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 20.63% | ||
| ROA | 10.63% | ||
| ROE | 18.84% | ||
| Debt/Equity | 0.18 |
29 analysts have analysed SAN.PA and the average price target is 101.26 EUR. This implies a price increase of 30.58% is expected in the next year compared to the current price of 77.54.
For the next year, analysts expect an EPS growth of 2.24% and a revenue growth -0.09% for SAN.PA
Sanofi engages in the research, production, and distribution of pharmaceutical products. The company is headquartered in Paris, Ile-De-France and currently employs 84,587 full-time employees. The company went IPO on 2002-07-01. The firm focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme.
SANOFI
46 Avenue de la Grande Armee
Paris ILE-DE-FRANCE FR
Employees: 82878
Phone: 33153774000
Sanofi engages in the research, production, and distribution of pharmaceutical products. The company is headquartered in Paris, Ile-De-France and currently employs 84,587 full-time employees. The company went IPO on 2002-07-01. The firm focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme.
The current stock price of SAN.PA is 77.54 EUR. The price decreased by -2.77% in the last trading session.
SAN.PA does not pay a dividend.
SAN.PA has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
SANOFI (SAN.PA) operates in the Health Care sector and the Pharmaceuticals industry.
SANOFI (SAN.PA) currently has 82878 employees.
SANOFI (SAN.PA) will report earnings on 2026-01-29, before the market open.